摘要
目的探讨急性淋巴细胞白血病患者骨髓单个核细胞白细胞介素-24(IL-24)的表达及临床意义。方法选取我院2018年1月至2020年6月收治的126例急性淋巴细胞白血病患者作为观察组,另选取同期70例健康体检者作为对照组,采集并分离骨髓单个核细胞。实时荧光定量PCR(qPCR)检测IL-24表达水平;分析骨髓单个核细胞中IL-24表达与急性淋巴细胞白血病临床病理特征及预后的关系。结果观察组IL-24水平显著低于对照组,且观察组中T系显著低于B系,未缓解期显著低于缓解期(P<0.05);观察组患者骨髓单个核细胞中IL-24表达量与性别、年龄、危险度分级比较差异无统计学意义(P>0.05);IL-24低表达组中位生存期为5.00个月,高表达组中位生存期为7.00个月。结论IL-24对急性淋巴细胞白血病患者骨髓单个核细胞具有明显的生长抑制、诱导凋亡作用。
Objective To investigate the expression and clinical significance of interleukin-24(IL-24)in bone marrow mononuclear cells of patients with acute lymphoblastic leukemia.Methods One hundred and twenty-six patients with acute lymphoblastic leukemia treated in our hospital from January 2018 to June 2020 were selected as the observation group,and 70 healthy people in the same period were selected as the control group.Bone marrow mononuclear cells were collected and isolated.The expression level of IL-24 was detected by real-time fluorescence quantitative PCR(qPCR).To analyze the relationship between the expression of IL-24 in bone marrow mononuclear cells and the clinicopathological features of acute lymphoblastic leukemia.To investigate the effect of IL-24 expression on the prognosis of patients.Results the level of IL-24 in the observation group was significantly lower than that in the control group,and the level of T system in the observation group was significantly lower than that in B system,and that in the non remission period was significantly lower than that in the remission period(P<0.05);There was no significant difference in the expression of IL-24 in bone marrow mononuclear cells between the observation group and gender,age and risk grade(P>0.05).The median survival time of IL-24 low expression group was 5.00 months and that of high expression group was 7.00 months.Conclusion IL-24 can significantly inhibit the growth and induce apoptosis of bone marrow mononuclear cells in patients with acute lymphoblastic leukemia.
作者
王萍
高红秀
郭东芳
岳文兵
WANG Ping;GAO Hongxiu;GUO Dongfang;YUE Wenbing(Department of Hematology, Zhumadian Central Hospital, Zhumadian 463000, China)
出处
《临床肿瘤学杂志》
CAS
2022年第2期129-132,共4页
Chinese Clinical Oncology
